The drugs of biological origins have attracted the attention of many pharmaceutical companies where it is essential to protect the heterogeneous nature and the optimal three dimensional structures of the different macromolecules. These molecules are used in both the investigation and therapy purposes, so their maximum activities should be maintained. This requires the designing of certain delivery formulations that suits the macromolecule nature, its target organ, the required dose and delivery route, and that's why the biotech companies invest millions of dollars towards achieving that. The fi rst main focal point of this article includes the recent developments in the formulation technologies for several biomacromolecule classes. The second focal point concentrates on the current considerations for optimizing their delivery for a maximum performance in the body.
INTRODUCTION
Biopharmaceuticals; from a classical point of view, are de ined as a subset of pharmaceuticals of inherent biological nature and manufactured using different biotechnological approaches including genetic engineering, monoclonal antibody production and vaccine bio-manufacturing [1, 2] . There's a confusion about the type of molecules classi ied as biopharmaceuticals and the others called drugs (pharmaceuticals of chemical origin) with diverse de initions and terms used on the level of standard regulations, science and industry. However, this article uses the classical de inition of the biopharmaceuticals which encompasses variety of molecules such as nucleic acids, proteins, peptides, vaccines, and polysaccharides [3] . The different types of the bioactive macromolecules, their developmental stages and recent applications were summarized by Walsh, 2003 and Ho and Gibaldi, 2013 [4, 5] . The term pharmaceutical or medicine will be used to include both the biopharmaceuticals and drugs. Moreover, the terms biological products and drugs will be used interchangeably with biopharmaceuticals as expressions only, not based on their scienti ic de initions. Production of the biopharmaceuticals dates back to the late 1700s with the irst time of vaccine production against smallpox in cows. Currently, over 900 medicine products are developed around the world against different diseases [6] . The biopharmaceutical products represent around 13 % of these drugs, and about 70 % of them belong to the potential irst-in-class products [7] . The recorded tremendous sales growth of this important class of pharmaceuticals was about 163 billion USD in 2012 [8] with invested 18.3 % of the sales in the Research and Development [9] .
As macromolecules with high molecular weights, the biopharmaceutical molecules have complex structures with high sensitivity to the surrounding conditions such as humidity, medium composition and temperature. Accordingly, maintaining certain storage, transportation and disposal conditions for the inal products is essential for amaintained stability and proper ef icacy with eliminating the unnecessary costs and wastage under certain Current General Manufacturing Practices (CGMP) [10, 11] . Handling of the different biological products as well follows certain policies which ensure cold chain compliance with effective management [12] . This requires the development of suitable formulation and delivery issues able to challenge the distinct properties of drugs, their high molecular weights, three dimensional (3D) structures, stability, and their various delivery routes for ef icient activities. Various dosage forms composed of one or more bioactive macromolecules as the active ingredient(s) with number of excipients have been designed with approved effects against number of diseases. The research in the ield of excipient manufacturing for improving the composition of these different forms to suite certain administration routes has attracted the attention of many researchers. These efforts concentrate on the excipient functionality within the dosage form, their safety and ef icacy accompanied with the quality and processability of new forms under certain regulatory and compendial approaches. This is supported by new evidences that number of excipients can act as active ingredients, in addition to their main functions such as controlling the lowability, stability, dissolution and palatability of the active drug [13] . This review therefore summarizes the stages of the therapeutic biopharmaceutical formulation starting with the candidate drugs and the several types of associated formulations focusing on the controlling factors for their designing, and how to characterize and control their properties. Moreover, the various classes of the used excipients along with the different administration routes have been discussed.
FORMULATION OF BIOPHARMACEUTICALS
Formulation is the process by which the active drug(s) is converted into a safe, ef icient and convenient form to be administrated by patient through its (their) combination with other chemical additives [14] . It involves the collaboration among the research chemists, analytical chemists, biologists and clinicians (Figure1). The background of the patient (e.g., sex, race, age) and location may also govern the formulation process and the inal required form.
The process consists of two main stages: Pre-formulation stage and the formulation stage itself:
The pre-formulation stage (Formulation selection)
Once a group of compounds have been identi ied as ef icient candidate drugs, their initial characteristics are assessed by the development scientists within a period which can last between three and six months [15] . As a pre-nomination stage, certain preformulation studies are performed to evaluate the structural properties, degradability, biophysical and physicochemical properties of the macromolecules [16] . Accordingly, the formulation type which can preserve the integrity and activity of the molecules with acceptable shelf-lives can be decided as the master formula. The process starts with the techniques used for analyzing the 1 ry , 2 ry and 3 ry structures of the candidate macromolecules, with testing the types and levels of the impurities. This is followed by assessing the functionalities of the different molecules using different screening techniques, along with studying their solubility and stability for the optimum developability of the desired biological products.
Based on the close interaction among the process research, analytical and medicinal chemistry, pharmaceutical science and safety assessment, various techniques can be used to characterize both the drug substances and their inal pharmaceutical products. The number of tests differs from an organization to another; some companies perform detailed characterization of the compounds, while others perform only the minimum essential number for a faster progressing into more advanced developmental stages [17, 18] . Despite that, there is a continuous development in the applied technologies to analyze the different compounds that are utilized if appropriate taking into consideration the lot-to-lot variations. The different protocols and their aims are abstracted below with summarizing the associated techniques in table 1.
Physicochemical and biophysical characterization protocols:
Due to the different types of biopharmaceuticals with their complex structures and properties, a single analytical method is not suf icient to assess the required parameters of the candidate molecules and the inal products. That's why a wide range of orthogonal approaches are used to characterize the different molecules from physicochemical, biophysical, and functional points of view in precise, accurate and robust ways [19, 20] . Some of these approaches belong to the quality assurance and control processes and can be used in combination with other appropriate tests for the inal dosage forms such as those for the uniformity and physical properties [21] . In general, setting the acceptance criteria for the biological drug substance/ product is amenable to changing, revision and improvement with gaining more experience on the studied molecules and products. The safety and ef icacy are the basic criteria by the biotech companies during these stages [22] .
The essential properties of the macromolecules are characterized once synthesized or extracted through the downstream processing by the related experts. Their identity is con irmed through detailed protocols to fully understand their behaviours in the body including the absorption, plasma protein binding, solubility and clearance by the liver and kidneys [23] . Determining the composition and primary structures of each type of molecules is essential for the further formulation stages. The structure and molecular dynamics are characterized using the Nuclear Magnetic Resonance (NMR); a powerful technique that was improved to suite the analysis and identi ication of very small amounts of macromolecules. Moreover, it has advanced usage in process monitoring and preformulation with essential usage in testing the product integrity during the formulation process [24, 25] . The usage of 2D NMR has excellent applications in polysaccharide, oligonucleotide and small proteins analysis with limitations for the larger proteins [26, 27] . Furthermore, to overcome some of the Mass Spectroscopy (MS) limitations in the biopharmaceutical analysis, it's employed coupled with NMR [28] .
The High Performance Liquid Chromatography (HPLC) is a very sensitive method for detecting the drug identity [29] . It's used in combination with Cation Exchange chromatography columns (CEX) to estimate the deamidation rates and detect the charge variants with monitoring the charge heterogeneity of the monoclonal antibodies [30] . In addition, hyphernated systems of HPLC or Liquid Chromatography with MS and/or NMR have been designed to characterize the different biomacromolecules, especially the glycosylated macromolecules [29, 31] .
The recombinant proteins isolated during the downstream processing often suffer from the instability leading to their aggregation and/or inactive conformation with impacts on the ef icacy and immunogenicity of the protein as well as the process economics [32] . Certain robust analytical techniques are used for monitoring and quanti ication of the resulting aggregate contents [33] . Although these analyses are performed throughout the entire lifecycle of the production, certain requirements for each assay are needed for each developmental stage [34] . Size Exclusion Chromatography (SEC)-HPLC instruments are used for testing the Aggregation/ degradation of the macromolecules with any levels of impurities [35] and they have met different developmental stages for the optimum band broadening [36] [37] [38] . The theory behind the usage of SEC, including the thermodynamics for the chromatographic separation of proteins and the kinetics and resolution of separation were summarized by [39] . Detecting the concentrations of different macromolecules, especially proteins can be achieved using UV detectors, where many Amino Acids (A.A), especially the aromatic class, give absorption for light in the UV region [40] . SEC-HPLC unit combined with U.V detector working at two different wavelengths was used for detecting and quanti ication of IgG1 protein including the monomer units and aggregates with a high linear range for the major species [41] .
This method of detection proved its higher sensitivity than the multiangle light scattering detectors.
The routine testing of the candidate molecule structures and whether the manufacturing process or the storage conditions may cause any changes in the molecular conformation and stability depend on both the Circular Dichroism (CD) and Fourier Transform Infrared Spectroscopy (FTIR) techniques. They are also ef icient in the distinguishing and quantitative analysis of the polymorphic forms of the different drug macromolecules can as well [42, 43] . In general, CD is more sensitive for the α-helices of proteins, while FTIR has more sensitivity for the β-sheet secondary structures [44, 45] . Moreover, FTIR de ines the unique certain functional groups within the structure of each molecule and is currently used for evaluating the purity of different biopharmaceuticals and whether any solvent is included within their samples [46] .
Due to the high stability and less solubility of the crystalline molecules than the amorphous analogues, the crystalline biological products are more desirable for the development [47] . The crystalline structure of the candidate macromolecules during the preformulation stage as well as that for the different products is analyzed with testing the stability of the solid forms. X-Ray powder Diffraction (XRD) is generally used for quanti ication of the crystallinity, but with limited sensitivity to the low degrees of the amorphous structures that can be tested using the thermal techniques (e.g., Differential Scanning Calorimetry (DSC)) [48] .
Dynamic light scattering (DLS) is a sensitive technique that depends on the scattering of light by the macromolecules which luctuates according to their sizes [49] . It's used for estimating the extent of aggregation/degradation of particles along with the size distribution within the tested samples, so it is important in testing the physical stability of the different biomacromolecules with studying the effects of different pH values and buffers [50] .
Choosing of excipients:
The excipients are essentially inactive substances of natural or synthetic origin which are added to the active drug/prodrug molecules during the manufacturing process or to the inal dosage form as bulking agents or illers for different purposes [13] . They have become basic components in the different drug formulations where they may act to stabilize the macromolecule during the manufacturing, storage and handling stages [53] . For instance, some inactive ingredients are added to the protein formulations for their protection from aggregation according to certain mechanisms summarized in the report of Ohtake et al. 2011, [54] . Others control the drug release from the formulation till reaching its target organ for ef icient performance and protecting the other organs with keeping their concentrations in the plasma below the toxic level [55] . Some excipients are added to improve the compliance of dosing, or to increase the patient acceptability for the drug by giving the product different colors and tastes. Others are added during the manufacturing to facilitate the powder lowability, ensure the physical stability of the inal products as well protect the drug from degradation over the shelf life. Furthermore, some excipients have therapeutic effects in addition to the active ingredients such as controlling the drug availability by modulating its solubility or permeability [56] , facilitating its absorption [57] or modifying the viscosity, especially with the poststerilization changes [58] .
The safety information and assessment criteria of the different excipients differ from one to another based on the structure, formulation type and the administration routes [59] . Accordingly, the International Pharmaceutical Excipient Council (IPEC) have categorized them into two main classes summarized in table 2 according to Nema and Brendel, 2010 [60] .
Whatever the class of excipient, the pre-clinical safety studies follows either the European or American IPEC-safety testing guidelines [61] [62] [63] . Different substances are used by the biotech companies as excipients majorly as inactive ingredients and some of them have therapeutic effects. These; alternatively, are organized based on the mode of action into the categories shown in table 3. Preservatives -Used for drug products with a humidity degree and with the diluent for the lyophilized proteins. -Inhibit the microbial growth with ensured product sterility throughout both the shelf life and the duration of drug usage [65] . -Used at certain concentrations to prevent the protein aggregation, especially with drugs of multi-doses *Antioxidants: Considered preservative agents for either scavenging of the oxygen-freeradicals [66] , or chelating agents for the trace metal, so protect from contaminants. [77] . Some salts are added to modify the viscosity of the different formulations [78] . -Addition of some buffering salts helps to stabilize some encapsulated proteins [79, 80] .
Different salts belonging to the Hofmeister series
Metal ions Certain types with certain concentrations are included in the formulation by forming coordination complexes when they are needed as cofactors for the essential actions of proteins [65] *Zn +2 ions in insulin formulations at pH 7.4 produces the Semilente form and at pH 5.5 produces the Ultralente form [81] . *Ca +2 ions (upto 100 mM) in rhDNase formulations [82] . *Ca
+2
and Sr +2 ions in Factor VIII formulations [83] .
Surfactants -Amphipathic molecules to prevent any surface induced degradation due to protein adsorption or denaturation [65] . -The surface layers of these molecules can prevent the adsorption of protein molecules at their interface with vial or air [84] .
*Fatty acid esters of sorbitan polyethoxylates Polysorbates 20, and 80.
Anti-adherents -Provide non-stick surfaces to reduce the adhesion between the drug powder, the punch faces and the tablet punches during the compression step of formulation [85] . -Prevent the agglomeration of the macromolecule chains during the manufacturing process. -Decrease water vapour permeability and drug dissolution rate [86, 87] .
Talc, Mg-stearate Binders Hold the ingredients of the tablet together to give fi nal formulae with suitable mechanical strength, especially with those of low drug loading [88, 89] .
*Disaccharides: Sucrose, Lactose. *Natural polysaccharides Starch, Cellulose, their derivatives) *Synthetic polymers:
Polyvinylpyrrolidone(PVP), Polyethylene glycol (PEG) *sugar alcohols:
Xylitol, Sorbitol Proteins: Gelatin Coatings -Protect the tablet ingredients from the environmental conditions (e.g., moisture, air and light). -Enhance the mechanical stability, taste and odour of the fi nal formulation [90] . -Control the drug release and are responsible for the identifi cation of some drug products [91] . -May be of the inner type used with tablets that will release their contents in the small intestine, not stomach [92] or external types.
-Some Anti-adherents, Surfactants and Coloring agents are considered types of the coatings.
*Outer fi lm coatings: Cellulose acetate, Hydroxypropyl methylcellulose (HPMC), Chitosan, Proteins (e.g., Gelatin coatings for capsules).
*Synthetic polymers. *Inner coatings: Phthalate, Shellac, Coloring agents -Chemical compatible agents with consistent molecular size and colours. -Improve the formulation stability and appearance to be acceptable by patients and make it easy to be identifi ed [93, 94] .
-Protect the light sensitive drugs [95] . -The container for the drug itself may have certain color for keeping the drug product stable.
-Synthetic dyes. -Natural coloring agents.
-Food pigments
For the biological drugs of similar properties (e.g., therapeutic peptides of different numbers of A.A), the effects of the molecular size on the solubility are tested [104] . Similarly, once a group of excipients were decided, their effects on the quality of solubility are tested to evaluate whether they cause salting-in or out of the drug [105] . Assessment of the drug dissolution behaviour as a function of temperature is also performed at a certain range focusing on the physiological temperature (37 o C) [106] .
The thermodynamic solubility can be tested by HPLC, while the DSC and XRD are used to analyze the undissolved material to monitor any phase changes, so the solvents for crystallization can be chosen as well [107, 47] .
Determination of the Partition and Distribution coef icients is essential to estimate diffusivity of the drugs and membrane permeability, especially for those absorbed by passive diffusion [108] . Different methods are used based on both simple and more advanced techniques with various computer routines [18] .
The different materials of different crystallinity can absorb water with different degrees. The amorphous forms have characterized irregular organization of the forming atoms making structures with high surface area, so attract more water than the corresponding more crystalline forms to be more hygroscopic [109] . As a result, these molecules are more susceptible to dissolution with higher rate of degradation and less chemical stability [110] . That's why the measurement of hygroscopicity of the candidate macromolecules within a certain time period and different temperatures is essential for testing their physical and chemical stability [111] . Accordingly, these measurements are performed in combination with the crystalline properties, thermal stability and molecular structure determination during the different stages of formulation for monitoring the overall process. The results represent important cornerstone for the designing of certain dosage formulae, especially on the transportation of the inal products and the needing for certain packaging forms [50] . The choice of certain hygroscopicity degrees nevertheless differs from a drug product to another and the decision is based on the whole tests not only the hygroscopic assays as well as the degree of hygroscopicity of the added excipients. Stability investigations: Many biological products, especially the native conformation of the therapeutic proteins have low thermodynamic stability with more susceptibility to change into unfolded inactive conformations accompanied with the loss of the optimal 3D architectures [115, 116] . These alterations may occur under high or relatively small changes in the surrounding conditions. These include temperature, medium composition (e.g., pH, salt content and presence of oxidizing agents at certain concentrations), light, agitation and shear strain [117, 118] . The puri ication, Disintegrants Important in the dispersion of drug product on becoming wet, so help in the release of its active contents within the digestive tract [96] .
*Cross-linked polymers: PVP, Cellulose derivatives, Alginate, Modifi ed starch. Flavouring agents -Natural or synthetic Substances to improve the acceptance of the patient for the drugs with unpleasant taste [97] by producing cooling sensation in the mouth [98] . -The type differs according to the required taste of the product (e.g., bitter, salty, sour, sweety).
Cherry, Peach, Raspberry, Apricot, Mint, Vanilla fl avours.
Glidants
Used during the drug product manufacturing to improve the powder fl owability by reducing the frictions between the particles [99] .
Starch, Colloidal fused silica, talc, Mg-Carbonate, Glycerides.
Lubricants -Substances to prevent the coherence between the different component particles and frictions with the tablet punches during the compaction. -Facilitate the tablet ejection [100] through different mechanisms [101, 102] . -They may slow the disintegration of the drug product (e.g., poor hydrophilic lubricants with no glidant or anti-adherent activities). [103] shows the lubricant effects on drug dissolution during the preformulation studies to choose the best types. Examples: Starch, Stearic acid and its salts processing, storage and delivery stages may lead to the drug degradation. This may be chemically (e.g., oxidation, hydrolysis, deamidation, disul ide rearrangement within the macromolecular structure) or physically through its destabilization with denaturation, aggregation and insoluble particulate formation [119] [120] [121] . Details and mechanisms of the biopharmaceutics degradation are summarized in the report of Parkins and Lashmar, 2000 [51] . These changes lead to the loss of activity which may accompany immunogenic response. Accordingly, long term stability studies for both the bulk drugs and inal products are performed to investigate their stability at different environmental and storage conditions, so both the shelf lives and expiry dates can be determined and improved [122] . These indings are essential for the next developmental stages for formulating a stable drug under CGMP and choosing the suitable inactive ingredients that can preserve its integrity and activity [123] . This also supports the clinical trials by guaranteeing the manufacturing of suitable products with high quality [124] and helps in the designing of proper protective packaging systems as well as in some post-marketing purposes.
In general, there is a group of real-time and accelerated stability compendial methods to test the various candidate biological drugs from physical, chemical, conformational, thermal, and photo-stability aspects taking into consideration their states of matter [125] [126] [127] . Even though there is a wide range of techniques available, the choice of speci ic types depends on the molecule characteristics, the required purity and potency as well as the expected type of degradants resulting from the main drug [128] . Moreover, subsets of valid methods for the characterization of drugs release can be also validated for usage in the stability studies. Examples for these protocols used in vaccines and gene-therapy products manufacturing are summarized in table 3 of Shintani report, 2013 [20] . In general, the forced degradation tests are performed prior to the stability studies to provide information on the drug degradability and share in deciding the best suitable stability protocols. In brief, different drug substance samples from different patches are tested under different experimental conditions (e.g., temperatures, pH, light intensity, humidity stress, oxygen and/or agitation stress as well as continuous freeze-thaw cycles for the frozen products). Analysis of the different degradants is used for getting information about the nature of drug degradation and its mechanism [19, 129] .
The accelerated stability protocols can test the candidate drug stability for a long time, compare the stability of different formulations and determine any possible degradation [130] . During the formulation development stage, the period of these studies differs among the companies based on the business size, time and the developmental pipelines sizes. The irst system is the conservative approach of the large pharma companies which evaluate the stability of candidate formulations within a long period (from 6 months to 2 years) under real and accelerated conditions (max. temperature: 25 o C) [131] . The best formulation of the highest purity is chosen for further manufacturing stages; however, despite the high con idence degree on choosing, it consumes long time and requires large number of samples with more personnel needs. The second system is the aggressive approach which consumes shorter period (15 days-2 months) for accelerated stability study of large number of trial formulations via statistical design of experiment under vigorous conditions suitable for the accelerated degradation [132] . This allows observing the optimum number of changes among the studied samples within a short period, followed by a longer period of stability study on the chosen formulations. This system is adopted by the small biotech companies without the time and resources required for the 1-2 year time stability study. Some problems may arise nevertheless in predicting the accelerated stability data for biological drugs, especially proteins as well as in correlating the obtained data under these conditions with those obtained after transforming to the real-time conditions [132] .
The formulation stage
This stage starts after complete characterization of the properties of different substances supposed to be used as biopharmaceutical drugs with understanding their possible inactivation mechanisms during the prenomination stage along with the needs of both the clinician and patient. It involves the designing of suitable formulation scheme for certain drug products with certain safety, convenience and ef icacy levels. This can be achieved with choosing the most suitable types of excipients, inal forms and technologies that suite the administration route, the nature and whether the drug delivery is for intracellular or extracellular effects. The formulation technologies thus can't be discussed separately from the different accompanied delivery routes summarized in the following section.
ADMINISTRATION ROUTES FOR THE BIOPHARMACEUTICAL PRODUCTS
Administration of the different biological products has several routes which generally begin with local delivery, and then the intracellular delivery for these drugs to perform their actions. Each route has its advantages and disadvantages based on the route itself or the used delivery technology as summarized in the report of Mitragotri et al., 2014 [133] . The injection route is the main way for the systemic delivery of the different biomacromolecules, but other routes have been borrowed as well from those used for the conventional pharmaceutical drugs such as oral, pulmonary and rectal delivery systems.
Injectable biopharmaceutical products and the applied technologies
Most biopharmaceutical products are delivered via injections, where the monoclonal antibodies are generally delivered via the intravenous injection, subcutaneous delivery, or vaccines through the intramuscular route. Some formulation technologies are dependent on non-covalent interactions between the drug and its matrix (e.g., Microparticles, nanoparticles, depot formulations), but others rely on the drug modi ication with different methods for easier delivery approaches.
Microparticles and nanoparticles:
These are used to control the sustained release of the different biological drugs (e.g., different peptides and some small molecules) and their life time in the body [134] , with modulating their pharmacokinetics [135] . In brief, the drug is encapsulated within particles made of mechanically strong, biodegradable and nontoxic polymers such as poly(lactic-co-glycolic acid) (PLGA), cyclodextrins, and polyanhydrides serving as diffusion barriers [136] . Different chemical and physical methods such as electrospraying, coacervation and solvent evaporation are used in the synthesis [137, 138] . In the case of nanoparticles, the carriers may be made of nano-polymeric, dendrimeric, or lipidic substances, generally used for the delivery of small biological molecules [139] [140] [141] . The release of protein from the microparticles was found to be affected by the porous structure of polymer, its molecular weight, degradation rate [133, 142] , the particle size, geometry, and surface properties [143] as well as the size of the loaded protein itself [144] [145] [146] .
Different micro/nano particles have different applications in the adjuvant administration through conjugation to the surface of some immune cells [147] , delivery of loaded certain adjuvants [147] [148] [149] and the controlled delivery of vaccines [150, 151] . The development of new micro/nano carriers for peptide, protein and oligonucleotide therapeutics is under progress to overcome the problems associated with the nanoparticle-mediated delivery through pegylation modi ication processes [152] [153] [154] .
Depot injections:
This technology was designed to overcome the problems associated with the delivery of large macromolecules through injections and can be used to deliver both the small and large biological drugs. As monolithic implantable depots, the active drug is either dissolved or dispersed in a polymeric matrix, and the drug release is controlled by its rate of diffusion and the type of polymer for sustained release [155] . Different injectable in-situ forming depots are reported in the references 40-46 of Mitragotri et al., 2014 report [133] .
Liquid jet injection:
This technique is based on needle-free liquid injectors used against infectious diseases and for delivery of some hormones [156, 157] . Some problems are associated with using this type of injection including the high cost and complexity of the method, unsuitability for the intravenous injection and the needing for personnel training as well as maintenance [158, 159] . On the other hand, some trials have started for solving these problems towards more improvements for this technology [160, 161] .
Delivery approaches for the small biological macromolecules: The factor controlling the half-life of any drug in the body is its resistance to the hepatic and renal clearance which; subsequently, affects the frequency of drug administration [162] . The small molecules can be modi ied by different methods for increasing their life in the circulation before degradation. The introduction of some new molecular groups may possibly affect the drug activity, purity, polydispersity of the product with unexpected induction of the immunogenic response, nonetheless. As a consequence, new safety tests along with new formulation technologies for the resulting complex structures are required with an ability to eliminate any possible immune-response. The modi ication methods are as follows:
A-Chemical modi ication
Depends on modifying the molecule through the covalent bonding to either a natural hydrophilic polymer (e.g., modi ied starch [162] and hyaluronic acid [163] ), or synthetic types majorly through PEGylation [164, 165] to increase the hydrodynamic radius of the drug, and thus reduce the glomerular iltration.
B-Fusion approaches
These approaches rely on the genetic fusion of the macromolecule with the Fc region of the IgG antibody or albumin. By this way, the therapeutic protein can be directly bioproduced without the need for further post-production modi ication [166, 133] .
Pumps: These are alternative devices for the delivery of injectable drugs to overcome the problems associated with any accidental injuries and needle-phobia [167] . These include the patch and implantable types for some hormone biotherapeutics such as insulin [168] [169] [170] and parathyroid hormone (PTH) [171, 172] . These devices are under continuous development to overcome some problems which may arise due to the limited sterility of skin with the needing to re ill more drug amount to the pump reservoir [173] .
Pulmonary delivery
This route is majorly used to deliver small molecules to the lung. Many biological products are at their clinical stage of development for the delivery of therapeutic peptides with indications for cystic ibrosis, in luenza virus, in lammation sarcoma, tuberculosis, and diabetes as summarized by Andrade et al., 2014 [174] in tables 7.1 and 7.2. The immunization through this route may provide excellent irst barrier in the prevention of some disease, especially in the developing countries [175, 176] ; however, delivery of vaccines through the pulmonary route is still under the early stages of development. In spite of the success in delivery of some biopharmaceuticals, more developmental stages are required to enhance its ef icacy in a safe and easy way to guarantee the optimum activity of the drug in its target tissues.
Nasal delivery route
Nasal mucosa has a high permeability and vascularization degree that enables the biopharmaceuticals to be systemically administered via the nasal route. Intranasal drug formulations for different macromolecules have been developed depending on whether the passage across the epithelium occurs via the trans-cellular or para-cellular mechanisms [177] [178] [179] . The blood low [180] , biological nature and physicochemical properties of drug [181] and possible degradation on passing through the lumen of the nasal cavity or across the nasal epithelial barrier affect the properties of these formulations as well [182, 183] . Examples for the formulations delivered via this route include those for insulin delivery for diabetes treatment [184] and for vaccination [185, 186] .
Rectal & Vaginal administration routes
The mechanism of drug absorption from rectum differs from that in the upper part of the Gastro Intestinal Tract (GIT) only due to the physiological circumstances [187] . Unlike the monolayer of epithelia in the intestine and the lung, the vaginal tract is covered with strati ied epithelia and it was found that the adaptive immunity in the vaginal mucosa; compared to other mucosal organs, is uniquely regulated [188] . Rectal immunization and intra-vaginal vaccination have been proven to be effective methods in rectal immunity and the immunity in the genital tract, respectively [189, 190] . These routes of delivery anyway face some problems due to much patient inacceptability and the interruption of absorption by defecation as well.
Transdermal delivery
This route is generally used to administer low macomolecular hydrophobic drugs, where some methods are currently used to temporarily disrupt the skin for their delivery. These include certain types of small peptides [57, 191] , electric ield and ultra-sound to deliver small biomolecules [192] [193] and micro-needles for the delivery of insulin, vaccines and PTH [194] . Some biopharmaceuticals in the form of PLGAencapsulated nanoparticles within hydrogels have recently been developed for skin administration [195] .
Oral delivery
Oral delivery of biological macromolecules faces some problems such as the enzymatic degradation in the GIT and the limited permeability with different absorption pathways through the intestinal epithelium which lead to their poor absorption and limited bioavailability [196] . Some techniques are now under development to improve the properties of drug formulation for oral administration and some additives are added to enhance the properties of the biopharmaceutical drugs for reaching the desired effects (Table 3) . These include the usage of mucoahesive devices to deliver some hormones [197] [198] and targeted nanoparticles for monoclonal antibody delivery. The surface of these particles is positively charged to bind with the negatively charged intestinal mucosa and easily permeate through it [199] [200] . Variables such as the compressional force or granulation process in the production of biopharmaceutical tablets can signi icantly affect the drug bioavailability as well [201] .
Local drug delivery
Despite the wide range of research regarding the different technologies for the systemic delivery of the biopharmaceuticals, the local delivery of some drugs such as the growth factors is the most suitable way for guaranteed targeting of speci ic tissues with optimum ef iciency.
Ocular delivery systems:
Periocular delivery is one of the administration routes for drugs to the subconjunctival, retrobulbar, and peribulbar locations using either implantation or injection techniques, but it may cause some complications such as hemorrhages in these locations nevertheless [202, 203] . The intravitreal administration method uses the same techniques to directly deliver the biopharmaceutial molecule to the vitreous and retina. In spite of that, the patients are at higher risk due to the possible hemorrages, cataract occurrence, and retinal detachment [204] . Ocular formulations in the form of nanoparticles (e.g., PLGA) have been recently designed with proved ex vivo corneal permeation and in vivo anti-in lammatory effects [205] .
Periodontal regeneration: Limited number of trials are now under progress for peridodontal gene therapy through the local delivery of nano/microparticles [206, 207] .
Intracellular delivery
After the systemic or local delivery of the macromolecule, its potential targets are mainly intracellular compartments including the mitochondrial, nuclear, and cytoplasmic molecules (e.g., enzymes, receptors, proteins, oligonucleotides) [208, 209] . To achieve the internalization of the macromolecules and increase the therapeutic index, different approaches have been designed. This aims to increase the permeability of the cellular membranes, activate the fusion between the drug and protein [210] and enhance the penetration to inside the cell through the usage of nanoparticles with special sizes [211] . In general, it was found out that the choosing of a certain apprach depends on the type of the drug macromolecule [133, 212] .
SUMMARY
The Formulation technologies and delivery routes of the different biopharmaceuticals for different diseases can't be studied separately. The chemical and physical properties of the drug, its biological activity, excipient types, and the administration routes should be essentially investigated as background information towards the designing of an ef icient drug formulation. This is important for maintaining the maximum activity of the drug for performing its function in its target tissue. This industrial ield of manufacturing has met many improvements; however, it still faces some challenges which require further research and development.
